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BACKGROUND: Precision medicine trials targeting the epidermal 
growth factor receptor (EGFR) in glioblastoma patients require selection for 
EGFR-amplified tumors. However, there is currently no golden standard in 
determining the amplification status of EGFR or EGFRvIII expression. Here, 
we aimed to determine which technique and which cut-offs are suitable to 
determine EGFR amplification status. MATERIAL AND METHODS: We 
compared fluorescent in-situ hybridization (FISH) and RT-qPCR data from 
patients screened for trial inclusion into the Intellance 2 clinical trial, with 
data from a panel-based next generation sequencing (NGS) platform (both 
DNA and RNA). RESULTS: By using data from >1000 samples, we show 
which cut-offs are optimal to determine EGFR gene amplification by FISH. 
Our data also show that gene amplification (as determined by FISH) correl-
ates with EGFR expression levels (as determined by RT-qPCR) with ROC 
analysis showing an under the curve area of up to 0.902. EGFR expres-
sion as assessed by RT-qPCR therefore may function as a surrogate marker 
for EGFR amplification. Our NGS data shows that EGFR copy numbers 
can strongly vary between tumors with levels ranging from 2 to more than 
100 copies per cell. Levels exceeding 5 gene copies can be used to define 
EGFR-amplification by NGS; below this level FISH detects very few (if any) 
EGFR amplified nuclei and none of the samples express EGFRvIII. CON-
CLUSION: Our data from central laboratories and diagnostic sequencing 
facilities, using material from patients eligible for clinical trial inclusion, help 
defining the optimal cut-off for various techniques to determine EGFR amp-
lification for diagnostic purposes.
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INTRODUCTION: Aberrant regulation of receptor tyrosine kinase 
(RTK) activity is characteristic of Glioblastoma (GBM). However, RTK-
based targeted therapies have been largely unsuccessful in GBM pa-
tients, partially due to the complexity and redundance of RTK signaling. 
LRIG1 (Leucine-rich Repeats and ImmunoGlobulindomains protein 1) is 
known as an endogenous inhibitor of epidermal growth factor receptor 
(EGFR) during health and disease, however its mechanism of action is 
poorly understood. We previously showed that the soluble form of LRIG1 
potently inhibits of GBM growth in vivo, irrespective of EGFR expres-
sion level and status, suggesting the involvement of other RTKs. Here, 
we aimed to shed light on the molecular mechanisms underlying its anti-
cancer activity. MATERIAL AND METHODS: We generated a recom-
binant human soluble LRIG1 protein by expressing LRIG1 ectodomain 
in insect cells via baculovirus infection and subsequent His-tag puri-
fication. rh-sLRIG1 was applied in the medium of classical GBM cell 
lines, patient-derived GBM stem-like cells and patient-derived 3D tumor 
organoids. Using different cell-based assays, cell proliferation, invasion, 
cell morphology, as well as protein expression and protein-protein inter-
actions were investigated. RESULTS: We find that recombinant sLRIG1 
efficiently reduces proliferation, invasion and viability of GBM cells and 
patient-derived organoids, and modulates cytoskeleton proteins and cell 
shape. In line with previous data, the effect of recombinant sLRIG1 is 
independent of EGFR expression. Interestingly sLRIG1 regulates several 
RTKs by direct protein downregulation, including AXL, while EGFR ex-
pression is not affected. At the molecular level, we find that sLRIG1 inter-
feres with AXL dimerization, while no protein interaction with EGFR is 
detected.  CONCLUSION: We identify AXL as a novel LRIG1 target and 
provide evidence that sLRIG1-mediated RTK downregulation requires 
direct protein-protein interaction. These data pave the way for a poten-
tial therapeutic application of recombinant sLRIG1 in the inhibition of 
growth factor signaling in GBM.
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BACKGROUND: In previous work we showed the prominence of the 
T-cell response in the formation of brain metastases of primary ER negative 
breast cancers (Mustafa et al, Acta Neuropathol 2018). We also showed that 
breast cancer cells co-cultured with stimulated T lymphocytes overexpress 
Guanylate-binding protein 1 (GBP1) accompanying increased trespassing 
ability through an in vitro blood-brain barrier (BBB) model. In addition, 
we demonstrated a predilection for metastasizing to brain of breast cancer 
cells that were co-cultured with activated T cells in a mouse model. We 
now scrutinize the importance of the IFNγ pathway for tresspassing of the 
tumor cells through the BBB following T cell contact. MATERIAL AND 
METHODS: Anti-hIFN-γ-IgA antibodies were used to neutralize the IFNγ 
effects on the tumor cells. The effects on the tumor cells is only due to na-
tive IFNγ produced by activated T cells, not by recombinant IFNγ. Since 
the IFNγ expression itself enhances its expression by the T cells, we blocked 
IFNγ receptors prior to adding CD3+ T cell conditioned media to the breast 
cancer cells. The receptor blocking was achieved by antibodies to the IFNγα 
and IFNγβ subunits. Activation of the STAT1 pathway was monitored 
by GBP1 expression. For functional read-out the in vitro BBB model was 
used. RESULTS: The presence of T-lymphocyte-secreted IFNγ in the pri-
mary breast cancer microenvironment activates the STAT1-dependent IFNγ 
pathway in breast cancer cells, endowing them with an increased ability 
to trespass the in vitro BBB. Moreover, direct inhibition of soluble IFNγ, 
or blocking of the IFNγ-specific receptor in breast cancer cells significantly 
decreases their ability to cross the BBB.  CONCLUSION: The results illus-
trate the specific action of T lymphocytes in the formation of cerebral me-
tastasis involves the IFNγ signaling pathway as one of the crucial entangled 
pathways Subsequent studies should aim at the interference with the IFNγ 
pathway to develop preventive strategies against the formation of cerebral 
metastases of breast cancer.
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BACKGROUND: Although extensive angiogenesis takes place in glial 
tumors, anti-angiogenic therapies have remained without the expected suc-
cess. In the peripheral circulation of glioma patients increased numbers of 
endothelial precursor cells (EPCs) are present, potentially offering targets 
for anti-angiogenic therapy (Zheng et al., Ann Neurol, 2007). However, for 
an anti-angiogenic therapy to be successful, the therapy should specifically 
target glioma-related EPC subsets and secreted factors. Here we compared 
the EPC subsets and plasma factors in the peripheral circulation of patients 
with gliomas to acute myocardial infarctions (representing fysiologic re-
generation). MATERIAL AND METHODS: We investigated the five most 
important EPC subsets and 21 angiogenesis-related plasma factors in per-
ipheral blood samples of 29 patients with glioma, 14 patients with myo-
cardial infarction and 20 healthy people as controls, by an advanced FACS 
protocol (Huizer et al., PlosOne 2018) and Luminex assay. RESULTS: In 
GBM patients all EPC subsets were elevated as compared to healthy 
subjects. In addition, HPC and KDR+ cell fractions were higher than in MI, 
while CD133+ and KDR+CD133+ cell fractions were lower. There were dif-
ferences in relative EPC fractions between the groups: KDR+ cells were the 
largest fraction in GBM while CD133+ cells were the largest fraction in MI. 
An increase in glioma malignancy grade coincided with an increase in the 
KDR+ fraction while the CD133+ cell fraction decreased relatively. Most 
plasma angiogenic factors were higher in GBM than MI patients. In both 
MI and GBM, the ratio of CD133+ HPCs correlated significantly with ele-
vated levels of MMP9. In the GBM patients MMP9 correlated strongly with 
levels of all HPCs. CONCLUSION: In conclusion, the data demonstrate 
that EPC traffic in patients with glioma is different from that in normal 
tissue regeneration. Therefore, the effects of glioma extent beyond the brain, 
and future therapies aimed at lowering KDR+ cells and HPCs may add to 
effective treatment.
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BACKGROUND: The expression of the matricellular protein periostin 
has recently been associated with glioma progression and angiogenesis. The 
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